Top five retina headlines in September

Clinical trial news for a geographic atrophy treatment candidate topped retina news in September, with studies regarding age-related macular degeneration also making headlines.

Here are the top five most read retina articles of the month on Healio.com/OSN:

1. Lampalizumab trial for geographic atrophy fails to meet endpoint

A phase 3 study of lampalizumab for geographic atrophy failed to meet its primary endpoint of reducing mean change in lesion area, Roche announced. Read more.

2. Treat-and-extend comparable to monthly injections in AMD

A multicenter 12-month phase 3b study showed that treat-and-extend administration of ranibizumab is “statistically noninferior and clinically comparable” with monthly treatment in patients with neovascular age-related macular degeneration. Read more.

3. Multicolor imaging detects features of AMD

Specificity values were high when multicolor retinal imaging was used to detect features of age-related macular degeneration. Read more.

4. Phenotypic characteristics associated with CFH variants

Genetic testing should be considered for patients with age-related macular degeneration and certain phenotypic characteristics, such as an extensive drusen area, to determine if they are suitable for future complement-inhibiting therapies. Read more.

5. NICE recommends Eylea for myopic choroidal neovascularization

The National Institute for Health and Care Excellence has given final positive recommendation for Eylea for the treatment of visual impairment due to myopic choroidal neovascularization. Read more.